$MRKR News

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer

All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

Marker Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

12 Health Care Stocks Moving In Monday's After-Market Session

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Highlights Nature Medicine Publication On Multi-Antigen T Cells In Pancreatic Cancer

Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely

HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate